ANGPT2

Angiopoietin-2 (ANGPT2), also known as ANG2 or AGPT2, is an antagonist of angiopoietin 1 (ANGPT1) and endothelial TEK tyrosine kinase (TIE-2, TEK). This protein damages the vascular remodeling function of ANGPT1 and may lead to endothelial cell apoptosis. ANGPT2 functions as a vessel-destabilizing molecule and is an essential regulator of blood vessel maturation. Initially, ANGPT2 is generated through endothelial cells and facilitates angiogenesis. It is low in common tissues but usually highly upregulated in the tumor vasculature.
In several cancers, improved circulating ANGPT2 has been related to poor prognosis and more invasive tumors, such as melanoma. It also serves a crucial role in inflammation. Also, patients receiving immune therapy are able to make antibodies to ANGPT2 as the result of treatment. Furthermore, ANGPT2 enables to offer compensatory resistance to antiangiogenesis therapy targeting VEGF. It has reported that high pretreatment serum ANGPT2 is correlated with decreased response rate and survival in metastatic colorectal cancer patients receiving antiangiogenesis therapy with bevacizumab. In addition, researchers have demonstrated that serum ANGPT2 is a potent biomarker for predicting clinical outcomes to immune checkpoint therapy as well as a possible target for synergistic combination treatments.
Gene ID: 285
UniProt ID: O15123